Stockreport

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF AN2 awarded third year of funding from Gates Foundation MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advanc [Read more]